Investment Analysis
🇺🇸 FDAExpert commentary and market intelligence for pharma strategy teams
Showing 1–9 of 9 articles
China: The Innovation Factor – Implications for Pharma BD and Investors
Utah Medical Board Scolded for Going Rogue with AI Criticism: Deal Implications for Pharma
House bill aims to crack down on China biotech deals
BIO International Convention 2026: A Preview of Biotech's Premier Partnering Event
CEPI Funds Three Ebola Vaccine Candidates to Accelerate Outbreak Response
FDA Leadership Vacuum: Navigating Uncertainty for Pharmaceutical Business Development
Biotech Stocks Facing FDA Decision in June 2026: Key Insights
Immunovant Shares Surge on Arthritis Trial Data: What It Means for Pharma
FDA Scrutiny Post-Market Data: Impact on Pharma Investment Strategies